• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Differences in the Evolution of Lung Function Before and After Treatment With Antifibrotics in Patients With Interstitial Lung Disease.

作者信息

Liendo-Martínez Katiuska Herminia, Baratech-Calpena Francisco Javier, Ji Zichen, Pedraza-Serrano Fernando, Caballero-Segura Francisco José, de Miguel-Díez Javier

机构信息

Respiratory Department, Gregorio Marañón General University Hospital, 28007 Madrid, Spain.

Faculty of Medicine, Complutense University of Madrid, 28040 Madrid, Spain.

出版信息

Open Respir Arch. 2023 Sep 18;5(4):100268. doi: 10.1016/j.opresp.2023.100268. eCollection 2023 Oct-Dec.

DOI:10.1016/j.opresp.2023.100268
PMID:37842287
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10568410/
Abstract
摘要

相似文献

1
Differences in the Evolution of Lung Function Before and After Treatment With Antifibrotics in Patients With Interstitial Lung Disease.间质性肺疾病患者使用抗纤维化药物治疗前后肺功能演变的差异
Open Respir Arch. 2023 Sep 18;5(4):100268. doi: 10.1016/j.opresp.2023.100268. eCollection 2023 Oct-Dec.
2
Tolerability and efficacy of second-line antifibrotics in patients with idiopathic pulmonary fibrosis.特发性肺纤维化二线抗纤维化药物的耐受性和疗效。
Pulm Pharmacol Ther. 2021 Dec;71:102099. doi: 10.1016/j.pupt.2021.102099. Epub 2021 Nov 15.
3
Antifibrotic Therapy: Is There a Role in Myositis-Interstitial Lung Disease?抗纤维化治疗：在肌炎相关性间质性肺疾病中有作用吗？
Respiration. 2021;100(9):923-932. doi: 10.1159/000515607. Epub 2021 May 5.
4
Antifibrotics for COVID-19 related lung fibrosis: Agents with benefits?抗纤维化药物治疗 COVID-19 相关肺纤维化：有效药物？
Adv Respir Med. 2021;89(2):231-233. doi: 10.5603/ARM.a2021.0023.
5
Antifibrotics in systemic sclerosis.系统性硬皮病中的抗纤维化药物。
Best Pract Res Clin Rheumatol. 2021 Sep;35(3):101671. doi: 10.1016/j.berh.2021.101671. Epub 2021 Apr 7.
6
Antifibrotic drugs in lung transplantation and chronic lung allograft dysfunction: a review.肺移植和慢性肺移植物功能障碍中的抗纤维化药物：综述。
Eur Respir Rev. 2021 Jun 1;30(160). doi: 10.1183/16000617.0050-2021. Print 2021 Jun 30.
7
Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment.真实世界研究分析接受抗纤维化治疗的肺功能保留的特发性肺纤维化患者的进展和生存情况。
Adv Ther. 2021 Jan;38(1):268-277. doi: 10.1007/s12325-020-01523-7. Epub 2020 Oct 24.
8
Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD.抗纤维化疗法与进行性纤维化间质性肺疾病（PF-ILD）：基于INBUILD研究
J Clin Med. 2021 May 25;10(11):2285. doi: 10.3390/jcm10112285.
9
Safety data from the use of antifibrotics in connective tissue disease-related interstitial lung disease: particular emphasis on association with immunosuppression.抗纤维化药物用于结缔组织病相关间质性肺疾病的安全性数据：特别强调与免疫抑制的关联。
ARP Rheumatol. 2023 Jan-Mar;2(1):88-91. Epub 2023 Jan 14.
10
Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.可能对进展性肺纤维化非特发性肺纤维化间质性肺疾病患者有抗纤维化药物的价值。
BMC Pulm Med. 2019 Nov 12;19(1):213. doi: 10.1186/s12890-019-0937-0.

本文引用的文献

1
Effects of Pirfenidone on Idiopathic Pulmonary Fibrosis Progression and Safety: Results of Multicenter Prospective Observational Study.吡非尼酮对特发性肺纤维化进展及安全性的影响：多中心前瞻性观察研究结果
Life (Basel). 2023 Feb 10;13(2):483. doi: 10.3390/life13020483.
2
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.特发性肺纤维化（更新版）和成人进展性肺纤维化：美国胸科学会/欧洲呼吸学会/日本呼吸学会/拉丁美洲胸科学会临床实践指南。
Am J Respir Crit Care Med. 2022 May 1;205(9):e18-e47. doi: 10.1164/rccm.202202-0399ST.
3
Idiopathic pulmonary fibrosis: Current and future treatment.特发性肺纤维化：当前和未来的治疗方法。
Clin Respir J. 2022 Feb;16(2):84-96. doi: 10.1111/crj.13466. Epub 2022 Jan 10.
4
Clinical course of IPF in Italian patients during 12 months of observation: results from the FIBRONET observational study.意大利患者在 12 个月观察期内的特发性肺纤维化临床病程：来自 FIBRONET 观察性研究的结果。
Respir Res. 2021 Feb 24;22(1):66. doi: 10.1186/s12931-021-01643-w.
5
Idiopathic pulmonary fibrosis: Disease mechanisms and drug development.特发性肺纤维化：疾病机制与药物研发。
Pharmacol Ther. 2021 Jun;222:107798. doi: 10.1016/j.pharmthera.2020.107798. Epub 2020 Dec 24.
6
Real-world experiences: Efficacy and tolerability of pirfenidone in clinical practice.真实世界的经验：吡非尼酮在临床实践中的疗效和耐受性。
PLoS One. 2020 Jan 30;15(1):e0228390. doi: 10.1371/journal.pone.0228390. eCollection 2020.
7
Idiopathic Pulmonary Fibrosis.特发性肺纤维化
N Engl J Med. 2018 May 10;378(19):1811-1823. doi: 10.1056/NEJMra1705751.
8
Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper.特发性肺纤维化的诊断标准：弗利彻协会白皮书。
Lancet Respir Med. 2018 Feb;6(2):138-153. doi: 10.1016/S2213-2600(17)30433-2. Epub 2017 Nov 15.
9
Spirometry. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR).肺量测定法。西班牙肺病学和胸腔外科学会（SEPAR）。
Arch Bronconeumol. 2013 Sep;49(9):388-401. doi: 10.1016/j.arbres.2013.04.001. Epub 2013 May 28.
10
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.吡非尼酮治疗特发性肺纤维化（CAPACITY）患者的两项随机试验。
Lancet. 2011 May 21;377(9779):1760-9. doi: 10.1016/S0140-6736(11)60405-4. Epub 2011 May 13.